SCHEMBL5385995

SCHEMBL5385995

Cc1cc(C=O)c(C)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.47
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GRIA1 P42261 1/20 0.45
GRIA2 P42262 1/20 0.45
GRIA3 P42263 1/20 0.45
GRIA4 P48058 1/20 0.45
TDP1 Q9NUW8 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
CD44 P16070 1/20 0.41
TSHR P16473 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
MPI P34949 1/20 0.39
ERN1 O75460 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22675490 0.91 PTPN1 (0.47) PTPN1ALDH1A1SMN1; SMN2GRIA1GRIA2
SCHEMBL13686228 0.88 GRIA1 (0.47) PTPN1ALDH1A1SMN1; SMN2GRIA1GRIA2
SCHEMBL10616671 0.86 TDP1 (0.46) PTPN1ALDH1A1SMN1; SMN2GRIA1GRIA2
SCHEMBL2884919 0.84 GRIA1 (0.56) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL23049567 0.83 TDP1 (0.48) PTPN1ALDH1A1SMN1; SMN2GRIA1GRIA2
SCHEMBL8332206 0.80 PTPN1 (0.44) PTPN1ALDH1A1SMN1; SMN2GRIA1GRIA2
SCHEMBL23827664 0.80 ERN1 (0.44) PTPN1ALDH1A1SMN1; SMN2GRIA1GRIA2
SCHEMBL3984058 0.80 ERN1 (0.53) PTPN1ALDH1A1TDP1CYP3A4CYP1A2
SCHEMBL24252419 0.80 PRKDC (0.47) PTPN1ALDH1A1SMN1; SMN2GRIA1GRIA2
SCHEMBL3687015 0.79 GRIA1 (0.52) ALDH1A1SMN1; SMN2GRIA1GRIA2GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-1544189-B1 Method for producing halogen-substituted aromatic aldehydes MITSUBISHI GAS CHEMICAL CO (JP) 2013-09-25 EP disclosed
US-7241925-B2 Method for producing halogen-substituted aromatic aldehyde MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2007-07-10 US disclosed
US-20050143605-A1 Method for producing halogen-substituted aromatic aldehyde MITSUBISHI GAS CHEMICAL CO., INC. (JP) 2005-06-30 US disclosed
EP-1544189-A1 Method for producing halogen-substituted aromatic aldehyde MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2005-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143605-A1 Method for producing halogen-substituted aromatic aldehyde CBR3, PAH, ALKBH3 PTPN1 3799/4885ALDH1A1 118/4885SMN1; SMN2 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.